- E-mailkristin.risa@uib.no
- Visitor AddressHaukeland universitetssykehus, Laboratoriebygget5009 Bergen
- Postal AddressPostboks 78045020 Bergen
Academic article
- (2022). Activity monitoring and patient-reported outcome measures in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients. PLOS ONE. 21 pages.
- (2021). A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. JCI Insight. 1-19.
- (2020). Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study. Frontiers in medicine. 1-15.
- (2019). B-lymphocyte depletion in patients with myalgic encephalomyelitis/chronic fatigue syndrome: A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 585-593.
- (2018). Rituximab serum concentrations and anti-rituximab antibodies during B-cell depletion therapy for myalgic encephalopathy/chronic fatigue syndrome. Clinical Therapeutics. 9.
- (2016). Serum BAFF and APRIL levels, T-lymphocyte subsets, and immunoglobulins after B-cell depletion using the monoclonal anti-CD20 antibody rituximab in myalgic encephalopathy/chronic fatigue syndrome. PLOS ONE.
- (2016). Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. JCI Insight.
- (2015). B-lymphocyte depletion in myalgic encephalopathy/chronic fatigue syndrome. An open-label phase II study with rituximab maintenance treatment. PLOS ONE.
- (2013). Identification of dynamic changes in proteins associated with the cellular cytoskeleton after exposure to okadaic acid. Marine Drugs. 1763-1782.
- (2011). Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLOS ONE. 13 pages.
More information in national current research information system (CRIStin)